PMV Pharmaceuticals, Inc.(PMVP)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
PMVP Stock Analysis & AI Quality Score
AI stock analysis and institutional research for PMV Pharmaceuticals, Inc. (PMVP), a Healthcare sector company. PMVP is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), PMV Pharmaceuticals, Inc. reports net income of $-18.0M, free cash flow of $-19.7M. Top institutional holders of PMVP by reported 13-F value include BML Capital Management,, TANG CAPITAL MANAGEMENT, Sio Capital Management,, based on the most recent SEC filings. PMVP trades on the Nasdaq exchange and files with the SEC under CIK 1699382. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PMVP daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PMV Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-18.0M
Free Cash Flow
Q1 2026
$-19.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+19.9% YoYOperating Income
-10.9% YoYEPS (Diluted)
+29.2% YoYTotal Assets
-29.2% YoYOp. Cash Flow
+19.6% YoY| Metric | FY 2024 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Net Income | $-58.7M +19.9% | $-73.3M -26.7% | $-57.8M -68.0% | $-34.4M -35.8% | $-25.4M -44.6% | $-17.5M |
| Operating Income | $-85.4M -10.9% | $-77.0M -32.2% | $-58.3M -66.8% | $-34.9M -31.2% | $-26.6M -41.0% | $-18.9M |
| EPS (Diluted) | $-1.14 +29.2% | $-1.61 -25.8% | $-1.28 +46.7% | $-2.40 | — | — |
| Total Assets | $191.3M -29.2% | $270.3M -18.5% | $331.6M -9.3% | $365.5M +254.8% | $103.0M | — |
| Operating Cash Flow | $-51.3M +19.6% | $-63.8M -36.9% | $-46.6M -42.2% | $-32.7M -48.4% | $-22.1M -45.4% | $-15.2M |
Get alerted when PMVP's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for PMV Pharmaceuticals, Inc. including:
Top Institutional Holders of PMVP
BML Capital Management, LLC
$6.6M5,320,000 shTANG CAPITAL MANAGEMENT LLC
$5.3M4,245,085 shSio Capital Management, LLC
$3.8M3,076,580 shArrowMark Colorado Holdings LLC
$3.6M2,872,764 shEuclidean Capital LLC
$3.3M2,627,643 shEversept Partners, LP
$2.9M2,348,360 shVANGUARD CAPITAL MANAGEMENT LLC
$2.4M1,974,906 shTWO SIGMA INVESTMENTS, LP
$2.3M1,884,530 shADAGE CAPITAL PARTNERS GP, L.L.C.
$2.3M1,860,000 shBlackRock, Inc.
$1.1M874,374 sh
| Fund | Value | Shares |
|---|---|---|
| BML Capital Management, LLC | $6.6M | 5,320,000 |
| TANG CAPITAL MANAGEMENT LLC | $5.3M | 4,245,085 |
| Sio Capital Management, LLC | $3.8M | 3,076,580 |
| ArrowMark Colorado Holdings LLC | $3.6M | 2,872,764 |
| Euclidean Capital LLC | $3.3M | 2,627,643 |
| Eversept Partners, LP | $2.9M | 2,348,360 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2.4M | 1,974,906 |
| TWO SIGMA INVESTMENTS, LP | $2.3M | 1,884,530 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $2.3M | 1,860,000 |
| BlackRock, Inc. | $1.1M | 874,374 |
More Healthcare Companies
View all Healthcare →Put PMVP on your watchlist
Track score changes the day PMV Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is PMVP a good stock to buy?
13F Pro's AI-powered analysis of PMV Pharmaceuticals, Inc. (PMVP) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PMVP are available on the PMVP stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own PMVP?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PMVP. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PMV Pharmaceuticals, Inc.'s investment landscape.